Novo Nordisk Spends $4.1bn on New Manufacturing Facility

With this new facility, the business will eventually be able to provide injectable therapies for obesity and other severe chronic illnesses, as well as increase its production capacity in the US.

With this development, Novo Nordisk’s present operations in North Carolina will have 1.4 million more square feet of production area, nearly doubling their current size.

The facility, which is expected to have rooftop solar panels, water strategies, and the newest technology, will improve the business’s clean production and final manufacturing capacity.

On the 56-acre site, preparation work has started, and building is anticipated to be finished in 2027 or 2029.

Novo Nordisk product supply, quality and IT executive vice-president Henrik Wulff commented: “Clayton was the first manufacturing site for Novo Nordisk in the US, and this new, large-scale investment confirms the continued importance of our production facilities there as cornerstones of our company’s growth.

He continued: “For decades, we have partnered to foster a well-trained, dedicated and diverse local workforce in North Carolina. In Clayton and across our global manufacturing sites, we are driven by one purpose: to deliver more for the millions of people living with chronic diseases – and this facility will help us achieve just that.”